The most useful thing about a new HIV-prevention guide may be a question it never asks: Why do you want to know about ...

For several years, pre-exposure prophylaxis against HIV (PrEP) has been a major success in preventing new cases. However, individuals on PrEP typically engage in riskier sexual behavior and thus are ...

Background Understanding the ‘real-world’ challenges of delivery of pre-exposure prophylaxis (PrEP) among men who have sex ...

In a far-reaching effort to understand the factors contributing to HIV transmission among sexual and gender minority (SGM) individuals and improve HIV prevention strategies, a team of scientists at ...

The number of people taking a vital anti-HIV drug has fallen by almost two-fifths in just one year in the aftermath of ...

Pre-exposure prophylaxis (PrEP) employs antiretroviral agents in HIV-negative individuals to avert viral acquisition. Initial efficacy trials of daily oral regimens combining emtricitabine and ...

Pre-exposure prophylaxis (PrEP) has emerged as a transformative biomedical intervention to prevent HIV infection among people at substantial risk. Its adoption reflects a complex interplay of clinical ...

HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...

Cuts from the U.S. and others have hit hard, with the number of people receiving PrEP dropping by 38% from 2024 to 2025, ...

The EUA was supported by primary data from the phase 3 PROVENT trial. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ...